{"id":"https://openalex.org/W2593435357","doi":"https://doi.org/10.1182/blood.v114.22.2911.2911","title":"Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.","display_name":"Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2593435357","doi":"https://doi.org/10.1182/blood.v114.22.2911.2911","mag":"2593435357"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.2911.2911","doi":"https://doi.org/10.1182/blood.v114.22.2911.2911","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.2911.2911","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Mayo Clinic, Scottsdale, AZ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Scottsdale, AZ, USA,","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024612499","display_name":"Animesh Dev Pardanani","orcid":"https://orcid.org/0000-0002-9084-4148","observed_orcids":["https://orcid.org/0000-0002-9084-4148"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Animesh D. Pardanani","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103463885","display_name":"Kebede Hussein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kebede Hussein","raw_affiliation_strings":["Internal Medicine, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014933846","display_name":"Wenting Wu","orcid":"https://orcid.org/0000-0003-4620-7595","observed_orcids":["https://orcid.org/0000-0003-4620-7595","https://orcid.org/0009-0001-9381-8703"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Wenting Wu","raw_affiliation_strings":["Mayo Clinic, Rochester, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045789519","display_name":"Susan Marie Schwager","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susan Schwager","raw_affiliation_strings":["Mayo Clinic, Rochester, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084606047","display_name":"William J. Hogan","orcid":"https://orcid.org/0000-0002-5841-4105","observed_orcids":["https://orcid.org/0000-0002-5841-4105"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William J Hogan","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016216479","display_name":"Ayalew Tefferi","orcid":"https://orcid.org/0000-0003-4605-3821","observed_orcids":["https://orcid.org/0000-0003-4605-3821"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayalew Tefferi","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5014933846","https://openalex.org/A5045789519"],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.302,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.66693397,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"114","issue":"22","first_page":"2911","last_page":"2911"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9869999885559082},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.984000027179718},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7940000295639038},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8920000195503235},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.7799999713897705},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.925000011920929},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.8349999785423279},{"id":"https://openalex.org/keywords/transfusion-dependence","display_name":"transfusion dependence","score":0.5460000038146973},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6790000200271606},{"id":"https://openalex.org/keywords/minimum-effective-dose","display_name":"minimum effective dose","score":0.6499999761581421},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.6909999847412109},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/jak-inhibitor-resistance","display_name":"JAK inhibitor resistance","score":0.4180000126361847},{"id":"https://openalex.org/keywords/spleen-volume-reduction","display_name":"spleen volume reduction","score":0.3100000023841858}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.8561840653419495},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8515291213989258},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.7101691961288452},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6500534415245056},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6071054935455322},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.5813731551170349},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5775579214096069},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4654897451400757},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.44144442677497864},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.3739314377307892},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.29685208201408386},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.11700439453125},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.10943165421485901}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.2911.2911","doi":"https://doi.org/10.1182/blood.v114.22.2911.2911","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.2911.2911","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2567946074","https://openalex.org/W2912342733","https://openalex.org/W2592894566","https://openalex.org/W2979340012","https://openalex.org/W2560066919","https://openalex.org/W2582102766","https://openalex.org/W2558411926","https://openalex.org/W2511522706","https://openalex.org/W567396713","https://openalex.org/W2005348994"],"abstract_inverted_index":{"Abstract":[0,1],"2911":[2],"Poster":[3],"Board":[4],"II-887":[5],"BACKGROUND:":[6],"Pomalidomide":[7],"(POM)":[8],"is":[9],"an":[10,28,460],"immune":[11],"modulatory":[12],"drug":[13],"(IMiD\u00ae":[14],"Immunomodulatory":[15],"compound)":[16],"recently":[17],"shown":[18],"to":[19,72,190,350,519,540,582,597],"improve":[20],"anemia":[21,336,473,498],"in":[22,27,119,142,161,163,335,352,446,454,472,521],"subjects":[23,173,201,242,280,310,325,354,360,411,458,495,535,544,571],"with":[24,37,95,202,441,526,572,580],"myelofibrosis":[25],"(MF)":[26],"adaptive":[29],"phase-2":[30],"trial":[31,71,86],"(0.5":[32],"mg":[33,293],"or":[34,38,138,396,476],"2.0":[35],"mg/d":[36,123,306,313,538,577,592,599,610],"without":[39,180],"prednisone;":[40],"Tefferi":[41],"et.":[42],"al.":[43],"JCO":[44],"2009)).":[45],"There":[46,450,529],"were":[47,59,124,146,174,188,204,229,238,266,282,326,530,561],"no":[48,127],"dose":[49,106,152,194,294,318,347,439,556,595],"limiting":[50],"toxicities":[51],"(DLT)":[52],"observed.":[53],"No":[54,333,426],"other":[55],"MF-features":[56],"(splenomegaly,":[57],"fibrosis)":[58],"identified/improved":[60],"even":[61],"at":[62,105,176,182,284,303,328,367,382,423,431,437,444,589],"the":[63,149,169,177,183,191,250,285,304,320,329,346,407,500,612],"highest":[64],"dose.":[65],"We":[66],"performed":[67],"a":[68,130,234,507,550,616],"subsequent":[69],"dose-escalation":[70],"determine":[73],"whether":[74],"higher":[75],"doses":[76,424,575,590,614],"of":[77,107,165,196,331,341,386,388,391,488,509,542,552,564],"POM":[78,102,363,574],"are":[79,578],"effective":[80,193],"and":[81,215,290,419,515],"well":[82],"tolerated.":[83],"METHODS:":[84],"The":[85,606],"was":[87,103,154,222,259,301,337,348,406,420,435,451,604],"classic":[88],"3":[89,91,186,211,279,308],"\u00d7":[90],"design":[92],"on":[93,357,362],"pts":[94],"symptomatic":[96,100],"MF":[97,203],"(anemia":[98],"and/or":[99,416,483],"splenomegaly).":[101],"started":[104],"2.5":[108,286],"mg/days":[109],"(d)":[110],"for":[111,480,491,615],"21":[112],"d":[113],"every":[114],"28":[115],"d.":[116],"Dose":[117],"increased":[118],"cohorts":[120,145],"by":[121,270],"0.5":[122,598,609],"done":[125],"if":[126],"subject":[128],"had":[129,208,233,243,412,496],"DLT":[131,162,297],"(\u2265grade-4":[132],"hematologic":[133],"toxicity,":[134],"\u2265grade-3":[135,139],"febrile":[136],"neutropenia":[137,414],"non-hematologic":[140],"toxicity)":[141],"cycle-1.":[143],"Subsequent":[144],"enrolled":[147,205,283,327],"until":[148],"maximum":[150],"tolerated":[151],"(MTD)":[153],"reached":[155],"(dose":[156],"level":[157,314,440],"before":[158],"that":[159],"resulting":[160],">1":[164],"6":[166],"subjects).":[167],"In":[168,570],"phase":[170],"2":[171,216,366,494,531],"portion,":[172],"treated":[175],"MTD,":[178],"those":[179],"response":[181,462],"MTD":[184,330],"after":[185,506,517,555,594],"cycles":[187,370],"lowered":[189],"minimal":[192],"(MED)":[195],"0.5mg/d.":[197,368],"RESULTS:":[198],"Subjects:":[199],"19":[200],"06/2008-03/2009.":[206],"14":[207],"primary":[209],"MF,":[210,214],"post-polycythemia":[212],"vera":[213],"post-essential":[217],"thrombocythemia":[218],"MF.":[219],"Median":[220,255],"age":[221],"67":[223],"y":[224],"(range,":[225,252,262,512],"43-83":[226],"y),":[227],"11":[228,237,534],"female":[230],"(58%).":[231,240],"16":[232,241],"JAK2-V617F":[235],"mutation.":[236],"RBC-transfusion\u2013dependent":[239],"palpable":[244,489],"splenomegaly,":[245],"median":[246,508,551],"12.5":[247],"cm":[248],"below":[249,499],"LCM":[251],"1-26":[253],"cm).":[254],"time":[256],"since":[257],"diagnosis":[258],"24":[260],"mo":[261,511],"1-173":[263],"mo).":[264],"15":[265],"considered":[267],"intermediate-high":[268],"risk":[269],"IWG-MRT":[271,461,501],"IPSS":[272],"(Cervantes":[273],"et":[274,464],"al,":[275,465],"Blood,":[276,466],"2009).":[277],"Phase-1:":[278],"each":[281],"mg/d,":[287],"3.0":[288,312],"g/d,":[289],"3.5":[291,305],"g/d":[292],"cohorts.":[295],"A":[296],"(bone":[298],"marrow":[299,343,404,429,585,602],"suppression)":[300],"seen":[302],"level.":[307],"additional":[309,324],"received":[311],"cohort":[315],"confirming":[316],"this":[317],"as":[319,611],"MTD.":[321],"Phase-2:":[322],"10":[323,379],"3.0mg/d.":[332],"improvement":[334,470],"seen,":[338],"possibly":[339],"because":[340,385],"bone":[342,403,428,584,601],"suppression.":[344,586],"Consequently,":[345],"decreased":[349],"0.5mg/d":[351,520],"7":[353,457,522,541],"(2":[355],"remain":[356,361],"3.0mg).":[358],"9":[359,455,565],"(all":[364],"but":[365],"104":[369],"have":[371],"been":[372],"given":[373],"(median,":[374],"4/":[375],"subject;":[376],"range,":[377],"2-11).":[378],"subjects,":[380],"all":[381],"\u22652.5mg/d":[383],"discontinued":[384],"lack":[387],"response/":[389],"withdrawal":[390],"consent":[392],"(N=5),":[393],"progression":[394],"(N=4)":[395],"unrelated":[397],"worsening":[398],"co-morbidities":[399],"(N=1).":[400],"Toxicity:":[401],"Dose-related":[402],"suppression":[405,430,603],"main":[408],"toxicity.":[409],"10/19":[410],"grade-3/-4":[413],"(N=8)":[415],"thrombocytopenia":[417],"(=3)":[418],"only":[421,516],"observed":[422],"\u22652.5mg/d.":[425],"substantial":[427],"0.5m/d.":[432],"Non-hematologic":[433],"toxicity":[434],"uncommon":[436],"any":[438],"grade-3":[442],"fatigue":[443],"3.0mg/d":[445],"1":[447,553],"subject.":[448],"Efficacy:":[449],"clinical":[452,469],"benefit":[453,504],"subjects.":[456],"achieved":[459],"(Tefferi":[463],"2006)":[467],"including":[468,524],"(CI)":[471],"(N=6;":[474],"rbc-transfusion-independence":[475],"hemoglobin":[477],"increase":[478],">2g/dL":[479],"\u22652":[481,492,576,591],"mo)":[482],"splenomegaly":[484],"(N=2;":[485],"\u226550%":[486],"reduction":[487,518,557,596],"component":[490],"months).":[493,559],"improved":[497],"CI-threshold.":[502],"Clinical":[503],"occurred":[505,549,588],"3.8":[510],"2.1-9.2":[513],"mo),":[514],"responders":[523,566],"both":[525],"spleen":[527],"responses.":[528],"responses":[532,548],"amongst":[533],"receiving":[536,545],"\u22652.5":[537],"compared":[539],"8":[543,563],"'1.0mg/d.":[546],"These":[547],"cycle":[554],"(1-3":[558],"Responses":[560],"durable:":[562],"continue":[567],"on-study.":[568],"CONCLUSIONS:":[569],"myelofibrosis,":[573],"associated":[579],"moderate":[581],"severe":[583],"Response":[587],"primarily":[593],"where":[600],"infrequent.":[605],"authors":[607],"suggest":[608],"preferred":[613],"phase-3":[617],"trial.":[618],"Disclosures:":[619],"Litzow:":[620],"Enzon:":[621],"Honoraria,":[622],"Research":[623],"Funding.":[624]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}